ArticleMolecules (Basel, Switzerland)2019
Apigenin Inhibits IL-31 Cytokine in Human Mast Cell and Mouse Skin Tissues.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- The inhibition of pathological IgE in allergic diseases by natural compounds.Natural products and bioprospecting · 2026Review
- Transmembrane protein 45b in peripheral sensory neurons selectively mediates IL-31-dependent chemical itch.Journal of anesthesia · 2026Article
- A pathway to next-generation mast cell stabilizers identified through the novel Phytomedical Analytics for Research Optimization at scale data platform.Frontiers in pharmacology · 2026Article
- A pathway to next-generation mast cell stabilizers identified through the novel Phytomedical Analytics for Research Optimization at Scale data platform.bioRxiv : the preprint server for biology · 2025Article
- Electroacupuncture exerts antipruritic and anti-inflammatory effects on atopic dermatitis by activating CB2 receptor.Chinese medicine · 2025Article
- Article
- Flavonoids in atopic dermatitis: mechanisms, delivery innovations, and translational strategies.Frontiers in pharmacology · 2025Review
- Apigenin accelerates wound healing in diabetic mice by promoting macrophage M2-type polarization via increasing miR-21 expression.Molecular and cellular biochemistry · 2024Article
- Analgesic and anti-inflammatory effects of galangin: a potential pathway to inhibit transient receptor potential vanilloid 1 receptor activation.The Korean journal of pain · 2024Article
- Mast cell-sensory neuron crosstalk in allergic diseases.The Journal of allergy and clinical immunology · 2024Review
- In Vitro Safety and Efficacy Evaluation of aPlants (Basel, Switzerland) · 2024Article
- Network Pharmacology, Molecular Docking and Experimental Verification Revealing the Mechanism of Fule Cream against Childhood Atopic Dermatitis.Current computer-aided drug design · 2024Article
- Exploring the Potential of Supercritical Fluid Extraction ofAntioxidants (Basel, Switzerland) · 2023Article
- Epicutaneous Sensitization and Food Allergy: Preventive Strategies Targeting Skin Barrier Repair-Facts and Challenges.Nutrients · 2023Review
- Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer.International journal of molecular sciences · 2023Review
- Exploring Standardized Scales and Serum Biomarkers to Evaluate Changes in Pruritus due to Eczema after Japanese Kampo Treatment: A Prospective Case Series.Complementary medicine research · 2022Article
- New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression.Journal of clinical medicine · 2021Review
- Valorization ofInternational journal of molecular sciences · 2020Article
- Importance of food in the control of inflammation in atopic dermatitis.Experimental and therapeutic medicine · 2020Article
- Luteolin and Apigenin Attenuate LPS-Induced Astrocyte Activation and Cytokine Production by Targeting MAPK, STAT3, and NF-κB Signaling Pathways.Inflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
IL-31 is a recently discovered cytokine that is produced not only in T-cells but also in mast cells. It is strongly implicated to play a key role in inflammatory diseases and in the pathogenesis of itch in atopic dermatitis. Apigenin, a flavonoid of plant origin has numerous biological applications. In this study, we showed that apigenin modulates IL-31 mRNA, protein expression, and release in stimulated human mast (HMC-1) by inhibiting the phosphorylation activation of MAPK and NF-κB. To determine whether apigenin has similar effects in vivo, using Compound 48/80, we developed an atopic dermatitis itch model in mice and found an increase in IL-31 expression in the skin. We also revealed that apigenin prevents the infiltration and degranulation of mast cells and suppressed mRNA and protein expression of IL-31 in the skin of mice. These results provide a new suggestion of the potential applicability of apigenin for treatment of various inflammatory diseases and itch mediated by IL-31.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.